John C Morris, MD

Director of the Section of Memory & Aging—Adult Neurology; the Harvey A and Dorismae Friedman Distinguished Professor of Neurology

Phone314-286-2683

Fax314-286-2763

Emailmorrisj@abraxas.wustl.edu

Additional Titles

  • Professor, Physical Therapy

Board Certifications

  • Internal Medicine - Certified
  • Neurology - Certified

Related Links

Recognition

  • Listed in Best Doctors in America, 2002-2013 (Best Doctors, Inc.)
  • Listed in America’s Top Doctors, 2002-2012 (Castle Connolly Medical Ltd.)
  • Recognized as one of the Top 44 Providers with the Highest Patient Satisfaction, Washington University School of Medicine, 2009-2012
  • Lifetime Achievement Award from the Alzheimer’s Association, 2004
  • Board of Directors, Alzheimer Association, Chicago, Illinois
  • MetLife Award for Medical Research in Alzheimer’s Disease (2004);
  • Potamkin Prize for Research in Pick’s, Alzheimer’s, and Related Dementias from the American Academy of Neurology (2005);
  • Physician-Scientist Lifetime Achievement Award, Barnes-Jewish Hospital Foundation, St. Louis, MO (2005);
  • Neville Grant Award for Clinical Excellence from Barnes-Jewish Hospital, St. Louis, MO (2006);
  • Carl and Gerty Cori Faculty Achievement Award, Washington University (2010).
  • 2013 Peter H. Raven Lifetime Achievement Award from the Academy of Science of St. Louis;
  • Washington University School of Medicine 2013 Second Century Award;
  • 2013 Medical & Scientific Honoree from the Alzheimer’s Association.

Publications

  • Benitez BA, Jin SC, Guerreiro R, Graham R, Lord J, Harold D, Sims R, Lambert JC, Gibbs JR, Bras J, Sassi C, Harari O, Bertelsen S, Lupton MK, Powell J, Bellenguez C, Brown K, Medway C, Haddick PC, van der Brug MP, Bhangale T, Ortmann W, Behrens T, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD, Haines JL, Turton J, Braae A, Barber I, Fagan AM, Holtzman DM, Morris JC; 3C Study Group; EADI consortium; Alzheimer’s Disease Genetic Consortium (ADGC); Alzheimer’s Disease Neuroimaging Initiative (ADNI); GERAD Consortium, Williams J, Kauwe JS, Amouyel P, Morgan K, Singleton A, Hardy J, Goate AM, Cruchaga C. Missense variant in TREML2 protects against Alzheimer’s disease. Neurobiol Aging. 2014 Jun;35(6):1510.e19-26.
  • Harari O, Cruchaga C, Kauwe JS, Ainscough BJ, Bales K, Pickering EH, Bertelsen S, Fagan AM, Holtzman DM, Morris JC, Goate AM; Alzheimer’s Disease Neuroimaging Initiative. Phosphorylated tau-aβ42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer’s disease in multiplex immunoassay panels of cerebrospinal fluid. Biol Psychiatry. 2014 May 1;75(9):723-31.
  • Brier MR, Thomas JB, Fagan AM, Hassenstab J, Holtzman DM, Benzinger TL, Morris JC, Ances BM. Functional connectivity and graph theory in preclinical Alzheimer’s disease. Neurobiol Aging. 2014 Apr;35(4):757-68.
  • Dobrowolska JA, Kasten T, Huang Y, Benzinger TL, Sigurdson W, Ovod V, Morris JC, Bateman RJ. Diurnal patterns of soluble amyloid precursor protein metabolites in the human central nervous system. PLoS One. 2014 Mar 19;9(3):e89998.
  • Morris JC, Blennow K, Froelich L, Nordberg A, Soininen H, Waldemar G, Wahlund LO, Dubois B. Harmonized diagnostic criteria for Alzheimer’s disease: recommendations. J Intern Med. 2014 Mar;275(3):204-13.
  • Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TL, Ghetti B, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Salloway S, Schofield PR, Sperling RA, Marcus D, Cairns NJ, Buckles VD, Ladenson JH, Morris JC, Holtzman DM; Dominantly Inherited Alzheimer Network. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer’s disease. Sci Transl Med. 2014 Mar 5;6(226):226ra30.
  • Cruchaga C, Karch CM, Jin SC, Benitez BA, Cai Y, Guerreiro R, Harari O, Norton J, Budde J, Bertelsen S, Jeng AT, Cooper B, Skorupa T, Carrell D, Levitch D, Hsu S, Choi J, Ryten M; UK Brain Expression Consortium, Hardy J, Ryten M, Trabzuni D, Weale ME, Ramasamy A, Smith C, Sassi C, Bras J, Gibbs JR, Hernandez DG, Lupton MK, Powell J, Forabosco P, Ridge PG, Corcoran CD, Tschanz JT, Norton MC, Munger RG, Schmutz C, Leary M, Demirci FY, Bamne MN, Wang X, Lopez OL, Ganguli M, Medway C, Turton J, Lord J, Braae A, Barber I, Brown K; Alzheimer’s Research UK Consortium, Passmore P, Craig D, Johnston J, McGuinness B, Todd S, Heun R, Kölsch H, Kehoe PG, Hooper NM, Vardy ER, Mann DM, Pickering-Brown S, Brown K, Kalsheker N, Lowe J, Morgan K, David Smith A, Wilcock G, Warden D, Holmes C, Pastor P, Lorenzo-Betancor O, Brkanac Z, Scott E, Topol E, Morgan K, Rogaeva E, Singleton AB, Hardy J, Kamboh MI, St George-Hyslop P, Cairns N, Morris JC, Kauwe JS, Goate AM. Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer’s disease. Nature. 2014 Jan 23;505(7484):550-4.
  • Storandt M, Balota DA, Aschenbrenner AJ, Morris JC. Clinical and psychological characteristics of the initial cohort of the Dominantly Inherited Alzheimer Network (DIAN). Neuropsychology. 2014 Jan;28(1):19-29.
  • Xiong C, Luo J, Gao F, Morris JC. Optimizing parameters in clinical trials with a randomized start or withdrawal design. Comput Stat Data Anal. 2014 Jan 1;69:101-113.
  • Mattsson N, Insel P, Tosun D, Zhang J, Jack CR Jr, Galasko D, Weiner M; Alzheimer’s Disease Neuroimaging Initiative. Effects of baseline CSF α-synuclein on regional brain atrophy rates in healthy elders, mild cognitive impairment and Alzheimer’s disease. PLoS One. 2013 Dec 31;8(12):e85443.
  • Roe CM, Fagan AM, Grant EA, Holtzman DM, Morris JC. CSF biomarkers of Alzheimer disease: “noncognitive” outcomes. Neurology. 2013 Dec 3;81(23):2028-31.
  • Su Y, D’Angelo GM, Vlassenko AG, Zhou G, Snyder AZ, Marcus DS, Blazey TM, Christensen JJ, Vora S, Morris JC, Mintun MA, Benzinger TL. Quantitative analysis of PiB-PET with FreeSurfer ROIs. PLoS One. 2013 Nov 6;8(11):e73377.
  • Benzinger TL, Blazey T, Jack CR Jr, Koeppe RA, Su Y, Xiong C, Raichle ME, Snyder AZ, Ances BM, Bateman RJ, Cairns NJ, Fagan AM, Goate A, Marcus DS, Aisen PS, Christensen JJ, Ercole L, Hornbeck RC, Farrar AM, Aldea P, Jasielec MS, Owen CJ, Xie X, Mayeux R, Brickman A, McDade E, Klunk W, Mathis CA, Ringman J, Thompson PM, Ghetti B, Saykin AJ, Sperling RA, Johnson KA, Salloway S, Correia S, Schofield PR, Masters CL, Rowe C, Villemagne VL, Martins R, Ourselin S, Rossor MN, Fox NC, Cash DM, Weiner MW, Holtzman DM, Buckles VD, Moulder K, Morris JC. Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease. Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):E4502-9.
  • Morris JC. Neurodegenerative disorders of aging: the down side of rising longevity. Mo Med. 2013 Sep-Oct;110(5):393-4. No abstract available.
  • Xiong C, van Belle G, Chen K, Tian L, Luo J, Gao F, Yan Y, Chen L, Morris JC, Crane P. Combining Multiple Markers to Improve the Longitudinal Rate of Progression-Application to Clinical Trials on the Early Stage of Alzheimer’s Disease. Stat Biopharm Res. 2013 Jan 1;5(1).

John C. Morris is the Harvey A. and Dorismae Hacker Friedman Distinguished Professor of Neurology, Professor of Pathology and Immunology, Professor of Physical Therapy, and Professor of Occupational Therapy at Washington University. He also is the Director and Principal Investigator of the Charles F. and Joanne Knight Alzheimer’s Disease Research Center.

Dr. Morris is the Principal Investigator for four multicomponent research grants, awarded by the National Institute on Aging (NIA), to study various aspects of Alzheimer disease. These grants include the Knight Alzheimer Disease Research Center, which Dr. Morris directs, two program projects, “Healthy Aging and Senile Dementia” and “Antecedent Biomarkers for AD: The Adult Children Study”; and a cooperative agreement that establishes an international consortium of leading academic centers, “The Dominantly Inherited Alzheimer Network” (DIAN). Dr. Morris directs all of these programs with the overarching goal of identifying Alzheimer disease in its earliest stages, prior to the onset of any symptoms, so that therapies can be initiated to prevent the occurrence of Alzheimer dementia.